A phase I/II, non-randomized, monocentric, open-label study of autologous CD34+ cells transduced with the G1XCGD lentiviral vector in patients with X-Linked Chronic Granulomatous Disease.
Latest Information Update: 22 Jul 2024
At a glance
- Drugs OTL 102 (Primary)
- Indications Chronic granulomatous disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genethon
Most Recent Events
- 24 Jun 2024 New trial record